Phreesia (NYSE:PHR) Posts Earnings Results, Misses Expectations By $0.05 EPS

Phreesia (NYSE:PHR) issued its quarterly earnings data on Monday. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.05), reports. The company had revenue of $127.07 million during the quarter, compared to analyst estimates of $126.75 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The business’s revenue was up 15.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.11) earnings per share.

Here are the key takeaways from Phreesia’s conference call:

• Phreesia hit major profitability milestones in fiscal 2026, including surpassing $100 million in Adjusted EBITDA, > $50 million in free cash flow, and delivering positive GAAP net income for the full year.
• The company lowered fiscal 2027 revenue guidance to $510–$520 million (from $545–$559M) due to shorter visibility and reduced spending commitments from certain pharmaceutical customers, notably in vaccines, public health, and other therapeutic areas.
• Despite the revenue cut, Phreesia maintained its fiscal 2027 Adjusted EBITDA outlook of $125–$135 million, citing built-in operating leverage and planned efficiency gains from AI and other cost actions.
• Phreesia completed a refinancing (new 5‑year, $275 million senior secured revolver) and has unused capacity it plans to prioritize toward long‑term value drivers such as debt paydown, growth investments, or share repurchases.
• The AccessOne acquisition is performing in line with expectations and remains central to Phreesia’s provider financing strategy, with plans to expand capital/securitization access to scale the offering across the provider base.

Phreesia Stock Performance

NYSE:PHR opened at $11.43 on Tuesday. Phreesia has a 52 week low of $10.75 and a 52 week high of $32.76. The company has a fifty day simple moving average of $12.51 and a two-hundred day simple moving average of $17.68. The company has a quick ratio of 2.44, a current ratio of 2.44 and a debt-to-equity ratio of 0.01. The company has a market cap of $689.36 million, a price-to-earnings ratio of -114.33 and a beta of 0.67.

Phreesia News Summary

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Phreesia reported positive GAAP net income of $2.3M for fiscal 2026 and strong cash generation — crossing $100M of Adjusted EBITDA and more than $50M of free cash flow (net cash from operations $78.8M). These profitability and cash milestones reduce financial risk and support reinvestment or M&A optionality. BusinessWire Release
• Positive Sentiment: Revenue grew 15.9% year-over-year to $127.07M in Q4, slightly above consensus revenue ($126.75M) — indicating demand for Phreesia’s platform remains intact even as margins and EPS were pressured. MarketBeat Earnings Summary
• Positive Sentiment: Management emphasized record revenue growth and strategic initiatives (including integration of the AccessOne acquisition) on the earnings call, which could support longer‑term revenue expansion if execution stays on track. Yahoo — Earnings Call Highlights
• Neutral Sentiment: Full Q4 earnings call transcript and slide deck are available for deeper review; dial into guidance details and margin drivers to size risk vs. upside. Useful for investors doing due diligence. Seeking Alpha Transcript
• Neutral Sentiment: Wall Street had already been lowering expectations ahead of the print; analysts revised forecasts which increases the sensitivity of the stock to forward guidance. Benzinga — Analyst Expectations
• Negative Sentiment: Phreesia missed EPS estimates ($0.02 reported vs. $0.07 expected), which spotlighted margin pressure despite revenue growth — a near-term earnings disappointment for investors focused on profitability. MarketBeat — EPS Miss
• Negative Sentiment: Management set 2027 revenue guidance to $510M–$520M and cited headwinds from network solutions plus the AccessOne integration — the trimmed outlook prompted steep share weakness and analyst re‑ratings. MSN — 2027 Guidance
• Negative Sentiment: News coverage highlights a sharp market reaction — shares hit all‑time lows and fell sharply (reports of ~22% intraday declines) after the guidance cut and earnings miss, signaling elevated near‑term downside risk until execution on guidance and integration is proven. Investing.com — Shares Tumble

Insiders Place Their Bets

In related news, General Counsel Allison C. Hoffman sold 6,176 shares of Phreesia stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $11.97, for a total value of $73,926.72. Following the completion of the transaction, the general counsel directly owned 163,485 shares in the company, valued at approximately $1,956,915.45. This trade represents a 3.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Balaji Gandhi sold 3,829 shares of the business’s stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $11.26, for a total value of $43,114.54. Following the transaction, the chief financial officer directly owned 146,740 shares of the company’s stock, valued at $1,652,292.40. The trade was a 2.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 70,358 shares of company stock valued at $1,123,569. 5.50% of the stock is owned by company insiders.

Institutional Trading of Phreesia

A number of large investors have recently made changes to their positions in PHR. Virtus Advisers LLC lifted its stake in Phreesia by 522.8% in the third quarter. Virtus Advisers LLC now owns 14,181 shares of the company’s stock worth $334,000 after acquiring an additional 11,904 shares during the last quarter. State of Tennessee Department of Treasury purchased a new stake in shares of Phreesia in the 2nd quarter valued at approximately $330,000. Caxton Associates LLP acquired a new stake in shares of Phreesia in the 1st quarter valued at $316,000. Prudential Financial Inc. acquired a new stake in shares of Phreesia in the 2nd quarter valued at $298,000. Finally, Globeflex Capital L P lifted its position in shares of Phreesia by 62.3% during the 2nd quarter. Globeflex Capital L P now owns 10,070 shares of the company’s stock worth $287,000 after purchasing an additional 3,866 shares during the last quarter. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PHR has been the topic of a number of research reports. Zacks Research cut Phreesia from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Needham & Company LLC reiterated a “buy” rating and issued a $35.00 price objective on shares of Phreesia in a report on Monday, December 8th. Robert W. Baird decreased their target price on Phreesia from $31.00 to $25.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 10th. DA Davidson lowered their target price on Phreesia from $35.00 to $30.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Finally, Wells Fargo & Company dropped their target price on Phreesia from $30.00 to $25.00 and set an “overweight” rating for the company in a research report on Thursday, March 26th. Seventeen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $28.65.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.